EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive Molecular Screening by Next Generation Sequencing of Gastrointestinal Stromal Tumors ( GISTs ): In Silico Analysis and Classification of Rare KIT Exon 11 Mutations

Maria Grazia Rodriquenz, Barbara Pasculli iD, Michelina Rendina, Francesco Petrizzelli iD, Tommaso Mazza, Antonio Petracca, Bartolomeo Augello, Michelina Coco, Teresa Balsamo, Anna Troiano, Magda Zanelli, Evaristo Maiello und 3 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Maria Grazia Rodriquenz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Oncology, Fondazione IRCCS Casa Sollievo Della Sofferenza, Foggia, Italy. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Proto-Oncogene Proteins c-kit, High-Throughput Nucleotide Sequencing, Gastrointestinal Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gastrointestinal stromal tumors (GISTs) originate from mesenchymal precursor cells of the gastrointestinal wall and account for approximately 3% of all gastrointestinal malignancies. In adults, these tumors most commonly harbor mutually exclusive activating mutations in KIT , PDGFRA , BRAF , or SDH ‐family genes. KIT and PDGFRA mutations are well‐established predictive biomarkers for response to tyrosine kinase inhibitors (TKIs). The advent of Next Generation Sequencing (NGS) has accelerated the identification of novel genetic alterations, improving disease characterization, providing prognostic and predictive information, and enabling detection of rare germline variants.

Methods

We conducted a retrospective analysis of 31 patients with GIST to evaluate the implementation of NGS testing and the interpretation of pathogenicity in real‐life clinical practice. Identified mutations were compared with publicly available databases, and rare KIT exon 11 variants underwent computational modeling to assess their impact on protein conformation and imatinib interaction. Germline testing was performed when indicated.

Results

In addition to common primary and secondary mutations in KIT and PDGFRA , three patients carried rare KIT exon 11 variants not previously classified in public databases: p.Gln556del (upstream of codons 557/559) and p.Asn566_Pro573del and p.Val569_Leu576_del (downstream), all located within the juxtamembrane (JM) domain. One patient harbored an S DHB c.287‐1G⟩C alteration resulting in aberrant splicing, also detected in the germline. The structural modeling predicted that all rare KIT exon 11 variants affected protein conformation and influenced imatinib interaction. Clinically, all three variants were associated with response to imatinib and met ACMG‐AMP criteria for pathogenicity as well as ASCO‐CAP tier 1 classification.

Conclusions

Our findings highlight the clinical relevance of integrating NGS into routine GIST management, particularly for the identification and interpretation of rare genetic variants. The study underscores the importance of data sharing and collective variant annotation to support accurate molecular classification, prognostic assessment, and therapeutic decision‐making for individual patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsProto-Oncogene Proteins c-kitHigh-Throughput Nucleotide SequencingGastrointestinal NeoplasmsMutationHumansMiddle AgedMaleFemaleExonsAgedRetrospective StudiesAdultImatinib MesylateComputer SimulationProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor alphaAged, 80 and over

Stichwörter der Autor:innen

KITPDGFRANext Generation Sequencing (NGS)SDH genesgastrointestinal stromal tumors (GISTs)structural bioinformatics

Substanzen

Proto-Oncogene Proteins c-kitKIT protein, humanImatinib MesylateProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor alpha

Autor:innen und Institutionen

  • Unit of Oncology, Fondazione IRCCS Casa Sollievo Della Sofferenza, Foggia, Italy.
  • Laboratory of Oncology, Fondazione IRCCS Casa Sollievo Della Sofferenza, Foggia, Italy.
  • Unit of Bioinformatics, Fondazione IRCCS Casa Sollievo Della Sofferenza, Foggia, Italy.
  • Computational Biology and Bioinformatics Unit, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.
  • Medical Genetics Unit, Fondazione IRCCS Casa Sollievo Della Sofferenza, Foggia, Italy.
  • Pathology Unit Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

ORCID-Profile: Barbara Pasculli, Francesco Petrizzelli, Paola Parrella

Förderung

  • Ministero della Salute
  • Ministry of Health

Zitieren

APA

Rodriquenz, M. G., Pasculli, B., Rendina, M., Petrizzelli, F., Mazza, T., Petracca, A., Augello, B., Coco, M., Balsamo, T., Troiano, A., Zanelli, M., Maiello, E., Graziano, P., Parente, P., & Parrella, P. (2025). Comprehensive Molecular Screening by Next Generation Sequencing of Gastrointestinal Stromal Tumors ( GISTs ): In Silico Analysis and Classification of Rare KIT Exon 11 Mutations. Cancer Medicine. https://doi.org/10.1002/cam4.71430

Vancouver

Rodriquenz MG, Pasculli B, Rendina M, Petrizzelli F, Mazza T, Petracca A, et al. Comprehensive Molecular Screening by Next Generation Sequencing of Gastrointestinal Stromal Tumors ( GISTs ): In Silico Analysis and Classification of Rare KIT Exon 11 Mutations. Cancer Medicine. 2025. doi:10.1002/cam4.71430

BibTeX
@article{Rodriquenz2025,
  author = {Rodriquenz, Maria Grazia and Pasculli, Barbara and Rendina, Michelina and Petrizzelli, Francesco and Mazza, Tommaso and Petracca, Antonio and Augello, Bartolomeo and Coco, Michelina and Balsamo, Teresa and Troiano, Anna and Zanelli, Magda and Maiello, Evaristo and Graziano, Paolo and Parente, Paola and Parrella, Paola},
  title = {Comprehensive Molecular Screening by Next Generation Sequencing of Gastrointestinal Stromal Tumors ( GISTs ): In Silico Analysis and Classification of Rare KIT Exon 11 Mutations},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71430}
}
Kostenlos starten →